BioArctic develops new antibody treatment for ALS
STOCKHOLM, Nov. 15, 2021 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today gave an update on the company’s development project ND3014. For the first time, it was announced that the project aims to develop selective antibody treatments targeting TDP-43, a protein that is…
Comments Off on BioArctic develops new antibody treatment for ALS